Halozyme Therapeutics, Inc. · NASDAQ:HALO
Torley Helen sold 40,000 Halozyme Therapeutics, Inc. shares (Form 4)
Traded Apr 1 to Apr 2, 2026 · Filed Apr 2, 2026
From Apr 1 to Apr 2, 2026, Torley Helen (Director, PRESIDENT AND CEO) sold 40,000 Halozyme Therapeutics, Inc. shares at an average US$64.81 for US$2.59M under a trading plan, leaving 767,780 shares. Filed Apr 2, 2026 (Form 4).
- Sold
- 40,000 shares
- Price
- US$64.81 average (US$64.06 to US$65.71)
- Value
- US$2.59M
- Holding after
- 767,780 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, PRESIDENT AND CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Common Stock | Option exercise | 20,000 | US$12.07 | 787,780 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 19,000 | US$65.36 | 768,780 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 1,000 | US$65.71 | 767,780 | Direct |
| Apr 2, 2026 | Common Stock | Option exercise | 20,000 | US$12.07 | 787,780 | Direct |
| Apr 2, 2026 | Common Stock | Sale | 15,800 | US$64.06 | 771,980 | Direct |
| Apr 2, 2026 | Common Stock | Sale | 4,200 | US$64.89 | 767,780 | Direct |
Source
Related
- Halozyme Therapeutics, Inc.
- Torley Helen
- Halozyme Therapeutics, Inc. shareholders
- Form 4 · Torley Helen · Oct 8, 2026
- Form 4 · Torley Helen · Sep 11, 2026
- Form 4 · Torley Helen · Aug 19, 2026
- Form 4 · Torley Helen · Jul 9, 2026
- Form 4 · Torley Helen · Jun 3, 2026
- Form 4 · Posard Matthew L. · Oct 2, 2026
- Form 4 · Daly James M · Oct 2, 2026
- Form 4 · Posard Matthew L. · Sep 17, 2026
- Form 4 · Appelhans Dannielle · Sep 2, 2026
- Schedule 13G · Vanguard Capital Management LLC · Apr 30, 2026